Treatment of allergic rhinitis in infants and children: Efficacy and safety of second-generation antihistamines and the leukotriene receptor antagonist montelukast

Hanna Phan, Matthew L. Moeller, Milap C. Nahata

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Allergic rhinitis (AR) affects a large percentage of paediatric patients. With the wide array of available agents, it has become a challenge to choose the most appropriate treatment for patients. Second-generation antihistamines have become increasingly popular because of their comparable efficacy and lower incidence of adverse effects relative to their first-generation counterparts, and the safety and efficacy of this drug class are established in the adult population. Data on the use of the second-generation antihistamines oral cetirizine, levocetirizine, loratadine, desloratadine and fexofenadine, and the leukotriene receptor antagonist montelukast as well as azelastine nasal spray in infants and children are evaluated in this review.These agents have been found to be relatively safe and effective in reducing symptoms associated with AR in children. Alternative dosage forms such as liquids or oral disintegrating tablets are available for most agents, allowing ease of administration to most young children and infants; however, limited data are available regarding use in infants for most agents, except desloratadine, cetirizine and montelukast. Unlike their predecessors, such as astemizole and terfenadine, the newer second-generation antihistamines and montelukast appear to be well tolerated, with absence of cardiotoxicities. Comparative studies are limited to cetirizine versus ketotifen, oxatomide andor montelukast. Although second-generation antihistamines and montelukast are deemed relatively safe for use in paediatric patients, there are some noteworthy drug interactions to consider when selecting an agent. Given the wide variety of available agents for treatment of AR in paediatric patients, the safety and efficacy data available for specific age groups, type of AR, dosage form availability and cost should be considered when selecting treatment for AR in infants and children.

Original languageEnglish (US)
Pages (from-to)2541-2576
Number of pages36
JournalDrugs
Volume69
Issue number18
DOIs
StatePublished - 2009

Fingerprint

montelukast
Non-Sedating Histamine H1 Antagonists
Leukotriene Antagonists
Cetirizine
Safety
fexofenadine
oxatomide
Dosage Forms
Pediatrics
azelastine
Astemizole
Loratadine
Terfenadine
Ketotifen
Nasal Sprays
Therapeutics
Patient Safety
Drug Interactions
Tablets
Age Groups

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Treatment of allergic rhinitis in infants and children : Efficacy and safety of second-generation antihistamines and the leukotriene receptor antagonist montelukast. / Phan, Hanna; Moeller, Matthew L.; Nahata, Milap C.

In: Drugs, Vol. 69, No. 18, 2009, p. 2541-2576.

Research output: Contribution to journalArticle

@article{4a2bf73975004a62a1a7f1362c64e66a,
title = "Treatment of allergic rhinitis in infants and children: Efficacy and safety of second-generation antihistamines and the leukotriene receptor antagonist montelukast",
abstract = "Allergic rhinitis (AR) affects a large percentage of paediatric patients. With the wide array of available agents, it has become a challenge to choose the most appropriate treatment for patients. Second-generation antihistamines have become increasingly popular because of their comparable efficacy and lower incidence of adverse effects relative to their first-generation counterparts, and the safety and efficacy of this drug class are established in the adult population. Data on the use of the second-generation antihistamines oral cetirizine, levocetirizine, loratadine, desloratadine and fexofenadine, and the leukotriene receptor antagonist montelukast as well as azelastine nasal spray in infants and children are evaluated in this review.These agents have been found to be relatively safe and effective in reducing symptoms associated with AR in children. Alternative dosage forms such as liquids or oral disintegrating tablets are available for most agents, allowing ease of administration to most young children and infants; however, limited data are available regarding use in infants for most agents, except desloratadine, cetirizine and montelukast. Unlike their predecessors, such as astemizole and terfenadine, the newer second-generation antihistamines and montelukast appear to be well tolerated, with absence of cardiotoxicities. Comparative studies are limited to cetirizine versus ketotifen, oxatomide andor montelukast. Although second-generation antihistamines and montelukast are deemed relatively safe for use in paediatric patients, there are some noteworthy drug interactions to consider when selecting an agent. Given the wide variety of available agents for treatment of AR in paediatric patients, the safety and efficacy data available for specific age groups, type of AR, dosage form availability and cost should be considered when selecting treatment for AR in infants and children.",
author = "Hanna Phan and Moeller, {Matthew L.} and Nahata, {Milap C.}",
year = "2009",
doi = "10.2165/9884960-000000000-00000",
language = "English (US)",
volume = "69",
pages = "2541--2576",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "18",

}

TY - JOUR

T1 - Treatment of allergic rhinitis in infants and children

T2 - Efficacy and safety of second-generation antihistamines and the leukotriene receptor antagonist montelukast

AU - Phan, Hanna

AU - Moeller, Matthew L.

AU - Nahata, Milap C.

PY - 2009

Y1 - 2009

N2 - Allergic rhinitis (AR) affects a large percentage of paediatric patients. With the wide array of available agents, it has become a challenge to choose the most appropriate treatment for patients. Second-generation antihistamines have become increasingly popular because of their comparable efficacy and lower incidence of adverse effects relative to their first-generation counterparts, and the safety and efficacy of this drug class are established in the adult population. Data on the use of the second-generation antihistamines oral cetirizine, levocetirizine, loratadine, desloratadine and fexofenadine, and the leukotriene receptor antagonist montelukast as well as azelastine nasal spray in infants and children are evaluated in this review.These agents have been found to be relatively safe and effective in reducing symptoms associated with AR in children. Alternative dosage forms such as liquids or oral disintegrating tablets are available for most agents, allowing ease of administration to most young children and infants; however, limited data are available regarding use in infants for most agents, except desloratadine, cetirizine and montelukast. Unlike their predecessors, such as astemizole and terfenadine, the newer second-generation antihistamines and montelukast appear to be well tolerated, with absence of cardiotoxicities. Comparative studies are limited to cetirizine versus ketotifen, oxatomide andor montelukast. Although second-generation antihistamines and montelukast are deemed relatively safe for use in paediatric patients, there are some noteworthy drug interactions to consider when selecting an agent. Given the wide variety of available agents for treatment of AR in paediatric patients, the safety and efficacy data available for specific age groups, type of AR, dosage form availability and cost should be considered when selecting treatment for AR in infants and children.

AB - Allergic rhinitis (AR) affects a large percentage of paediatric patients. With the wide array of available agents, it has become a challenge to choose the most appropriate treatment for patients. Second-generation antihistamines have become increasingly popular because of their comparable efficacy and lower incidence of adverse effects relative to their first-generation counterparts, and the safety and efficacy of this drug class are established in the adult population. Data on the use of the second-generation antihistamines oral cetirizine, levocetirizine, loratadine, desloratadine and fexofenadine, and the leukotriene receptor antagonist montelukast as well as azelastine nasal spray in infants and children are evaluated in this review.These agents have been found to be relatively safe and effective in reducing symptoms associated with AR in children. Alternative dosage forms such as liquids or oral disintegrating tablets are available for most agents, allowing ease of administration to most young children and infants; however, limited data are available regarding use in infants for most agents, except desloratadine, cetirizine and montelukast. Unlike their predecessors, such as astemizole and terfenadine, the newer second-generation antihistamines and montelukast appear to be well tolerated, with absence of cardiotoxicities. Comparative studies are limited to cetirizine versus ketotifen, oxatomide andor montelukast. Although second-generation antihistamines and montelukast are deemed relatively safe for use in paediatric patients, there are some noteworthy drug interactions to consider when selecting an agent. Given the wide variety of available agents for treatment of AR in paediatric patients, the safety and efficacy data available for specific age groups, type of AR, dosage form availability and cost should be considered when selecting treatment for AR in infants and children.

UR - http://www.scopus.com/inward/record.url?scp=71849100688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71849100688&partnerID=8YFLogxK

U2 - 10.2165/9884960-000000000-00000

DO - 10.2165/9884960-000000000-00000

M3 - Article

C2 - 19943707

AN - SCOPUS:71849100688

VL - 69

SP - 2541

EP - 2576

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - 18

ER -